Aktie 859507 VISIONEERING TECHNOLOGIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Visioneering Technologies, Inc.

Aktien

859507

AU000000VTI2

VTI

Markt geschlossen - Australian S.E.
Andere Börsenplätze
 07:52:47 02.05.2024 		% 5 Tage % 1. Jan.
0,096 AUD -4,00 % Intraday Chart für Visioneering Technologies, Inc. -45,14 % -61,60 %
24.04. Transcript : Visioneering Technologies, Inc., Q1 2024 Earnings Call, Apr 23, 2024
28.02. Visioneering Technologies, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study
Visioneering Technologies Issues Part of Shortfall from Rights Offering
VTI Announces Positive Interim 1-Year Data from the PROTECT Clinical Trial at American Academy of Optometry Annual Meeting
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
VTI Appoints Dr. Juan Carlos Aragón as CEO and Executive Director
Visioneering Technologies Appoints CEO
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Visioneering Technologies, Inc. Announces Board Changes
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
Visioneering Technologies : Appendix 4C and Business Activity Report - Jun-22 Qtr
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control
Visioneering Technologies, Inc. Announces Board Changes
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 859507 Aktie
  4. Nachrichten Visioneering Technologies, Inc.
  5. Andere Sprachen